2023
Burnout in US hematologists and oncologists: impact of compensation models and advanced practice provider support
Lee A, Masselink LE, De Castro LM, Marshall AL, Connell NT, Dent GA, Fritz J, Homer M, Lucas TL, Naik RP, Nelson M, O’Connell C, Rajasekhar A, Reynolds R, Sharma D, Smith M, Weeks LD, Erikson CE. Burnout in US hematologists and oncologists: impact of compensation models and advanced practice provider support. Blood Advances 2023, 7: 3058-3068. PMID: 35476017, PMCID: PMC10331414, DOI: 10.1182/bloodadvances.2021006140.Peer-Reviewed Original ResearchMeSH KeywordsBurnout, ProfessionalFemaleHumansJob SatisfactionMaleOncologistsPhysiciansSurveys and QuestionnairesUnited StatesConceptsCommunity physiciansProvider supportMultivariate logistic regression modelOverall survey response rateClinical support staffCommunity practiceLogistic regression modelsHigh burnoutUS hematologistsSurvey response rateComplete responseFemale genderAMA MasterfileResponse rateSignificant associationHematologistsOncologistsFinal analysisPhysiciansLarge-scale studiesProvider UtilizationPractice surveyAmerican SocietyOne-thirdPhysician compensation
2021
Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021, 137: 969-976. PMID: 33280030, PMCID: PMC7918179, DOI: 10.1182/blood.2020006052.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCombined Modality TherapyCost-Benefit AnalysisDecision TreesDrug CostsDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansImmunosuppressive AgentsLength of StayMaleMarkov ChainsMiddle AgedModels, EconomicMulticenter Studies as TopicPlasma ExchangePurpura, Thrombotic ThrombocytopenicRecurrenceRituximabSingle-Domain AntibodiesStandard of CareUnited StatesYoung AdultConceptsIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeVon Willebrand factorRelapse rateThrombocytopenic purpuraClinical trialsMajor randomized clinical trialsThrombotic microangiopathy leadingEnd-organ damageWillebrand factorPlatelet count recoveryRandomized clinical trialsHealth system costsOne-way sensitivity analysesCost-effectiveness ratioLife-threatening diseaseProbabilistic sensitivity analysesCost-effectiveness analysisHospital lengthCount recoveryPlasma exchangeTPE treatmentTTP patientsImmunomodulatory agents
2019
Trends and factors affecting the US adult hematology workforce: a mixed methods study
Sharma D, Wallace N, Levinsohn EA, Marshall AL, Kayoumi K, Madero J, Homer M, Reynolds R, Hafler J, Podoltsev NA, Lee AI. Trends and factors affecting the US adult hematology workforce: a mixed methods study. Blood Advances 2019, 3: 3550-3561. PMID: 31738829, PMCID: PMC6880914, DOI: 10.1182/bloodadvances.2019000307.Peer-Reviewed Original ResearchConceptsHematology/oncology fellowsBenign hematologyOncology fellowsASH annual meetingClinical care modelsMixed-methods studyMajority of fellowsAdult hematologistsSeparate focus groupsCare modelClinical careMethods studyFellowship program directorsFocus group participantsHematologyMore fellowsFellowship trainingSingle training programOncologyGroup participantsLongitudinal studyAmerican SocietyNational studyOncology facultyFocus group discussions